表紙
市場調查報告書

PharmSource:對CMO (醫藥品受託製造機關) 的新藥許可證引進趨勢 (2020年版)

PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition

出版商 GlobalData 商品編碼 929725
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
PharmSource:對CMO (醫藥品受託製造機關) 的新藥許可證引進趨勢 (2020年版) PharmSource: Contract Manufacturing of Novel In-Licensed Drugs - 2020 Edition
出版日期: 2020年02月24日內容資訊: 英文 24 Pages
簡介

本報告提供全球CMO (醫藥品受託製造機關) 產業中,MNE (含有新有效成分醫藥品)的製造許可證引進 (引入授權) 情形相關分析,NME的認證、授權的動向,及整體契約締結數量趨勢 (2014∼2018年),各分子類型的趨勢,製藥企業的內製/外包化的趨勢,潛在的市場規模等資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 表格一覽

第3章 圖的一覽

第4章 摘要整理

第5章 簡介

第6章 MNE (新化合物)的許可證提供趨勢 (2014∼2018年)

第7章 授權交易的時機

  • 授權交易和外包的年表

第8章 NME的外包化的趨勢:各生產形態

  • 產品裡面制/外包的趨勢:各企業市值

第9章 各分子類型的趨勢

  • 許可證引進 (引入授權)的趨勢:各分子類型
    • 未來分析:細胞治療、基因治療
  • 醫藥品廠商:各分子類型

第10章 企業分析

第11章 結論

第12章 分析方法的相關注記

第13章 附錄

目錄
Product Code: GDPS0030MAR

This expert trend report explores in-licensing trends among FDA New Molecule Entity (NME) approvals 2014-2018, and analyzes how licensing patterns affect propensity to outsource finished dose manufacture. This report is critical for establishing an understanding of the ways bio/pharmaceutical companies source their drugs, and the factor that make them more likely to engage a contract manufacturing organization (CMO).

Scope

  • CMO executives who must have a deep understanding of the NME approvals landscape to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Pharmaceutical and biotech companies evaluating potential licensing deals as a licensor or licensee.
  • Investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

  • Overview of novel drugs (NMEs) approved by FDA 2014-2018
  • Detailed analysis of dose outsourcing likelihood by: licensing status, market cap, molecule type
  • Spotlight on licensing deals and outsourcing propensity
  • Detailed methodology explains use of data from the GlobalData Pharma Intelligence Center databases

Table of Contents

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Introduction

6 Licensing of New Molecular Entities Approved 2014-2018

7 Timing of Licensing Deals

  • 7.1 Chronology of Licensing and Outsourcing

8 Outsourcing Propensity by Source of NME

  • 8.1 Product Source and Outsourcing Propensity by Market Cap

9 Trends by Molecule Type

  • 9.1 In-Licensing by Molecule Type
    • 9.1.1 Spotlight On: Cell and Gene Therapies
  • 9.2 Dose Manufacture by Molecule Type

10 Company Analysis

11 What It Means

12 Notes on Methodology

13 Appendix

  • 13.1 Bibliography
  • 13.2 Primary Research - Key Opinion Leaders Featured in This Report
  • 13.3 About the Authors
  • 13.4 Contact Us
  • 13.5 Disclaimer

List of Tables

  • Table 1: Breakdown of Approvals 2014-2018 by Company Market Cap Band

List of Figures

  • Figure 1: Source of NMEs Approved 2014-2018
  • Figure 2: Source of NMEs Approved 2014-2018, by Year
  • Figure 3: Status of Approved In-Licensed NMEs at Time of Licensing Deal, 2014-2018
  • Figure 4: Status of Approved In-Licensed NMEs at Time of Li